Home > Publications database > On the use of the healthy lifestyle index to investigate specific disease outcomes. > print

001     291781
005     20241120114551.0
024 7 _ |a 10.1038/s41598-024-66772-w
|2 doi
024 7 _ |a pmid:39009699
|2 pmid
024 7 _ |a pmc:PMC11250810
|2 pmc
024 7 _ |a altmetric:165420591
|2 altmetric
037 _ _ |a DKFZ-2024-01517
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Viallon, Vivian
|b 0
245 _ _ |a On the use of the healthy lifestyle index to investigate specific disease outcomes.
260 _ _ |a [London]
|c 2024
|b Macmillan Publishers Limited, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721656313_25597
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The healthy lifestyle index (HLI), defined as the unweighted sum of individual lifestyle components, was used to investigate the combined role of lifestyle factors on health-related outcomes. We introduced weighted outcome-specific versions of the HLI, where individual lifestyle components were weighted according to their associations with disease outcomes. Within the European Prospective Investigation into Cancer and Nutrition (EPIC), we examined the association between the standard and the outcome-specific HLIs and the risk of T2D, CVD, cancer, and all-cause premature mortality. Estimates of the hazard ratios (HRs), the Harrell's C-index and the population attributable fractions (PAFs) were compared. For T2D, the HR for 1-SD increase of the standard and T2D-specific HLI were 0.66 (95% CI: 0.64, 0.67) and 0.43 (0.42, 0.44), respectively, and the C-index were 0.63 (0.62, 0.64) and 0.72 (0.72, 0.73). Similar, yet less pronounced differences in HR and C-index were observed for standard and outcome-specific estimates for cancer, CVD and all-cause mortality. PAF estimates for mortality before age 80 were 57% (55%, 58%) and 33% (32%, 34%) for standard and mortality-specific HLI, respectively. The use of outcome-specific HLI could improve the assessment of the role of lifestyle factors on disease outcomes, thus enhancing the definition of public health recommendations.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cancer
|2 Other
650 _ 7 |a Cardiovascular diseases
|2 Other
650 _ 7 |a Composite score
|2 Other
650 _ 7 |a Healthy lifestyle index
|2 Other
650 _ 7 |a Lifestyle factors
|2 Other
650 _ 7 |a Mortality
|2 Other
650 _ 7 |a Type 2 diabetes
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Healthy Lifestyle
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neoplasms: mortality
|2 MeSH
650 _ 2 |a Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Cardiovascular Diseases: mortality
|2 MeSH
650 _ 2 |a Cardiovascular Diseases: epidemiology
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Diabetes Mellitus, Type 2: mortality
|2 MeSH
650 _ 2 |a Diabetes Mellitus, Type 2: epidemiology
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Proportional Hazards Models
|2 MeSH
650 _ 2 |a Europe: epidemiology
|2 MeSH
650 _ 2 |a Mortality, Premature
|2 MeSH
650 _ 2 |a Life Style
|2 MeSH
700 1 _ |a Freisling, Heinz
|b 1
700 1 _ |a Matta, Komodo
|b 2
700 1 _ |a Nannsen, Anne Østergaard
|b 3
700 1 _ |a Dahm, Christina C
|b 4
700 1 _ |a Tjønneland, Anne
|b 5
700 1 _ |a Eriksen, Anne Kirstine
|b 6
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 7
|u dkfz
700 1 _ |a Katzke, Verena A
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 8
|u dkfz
700 1 _ |a Schulze, Matthias B
|b 9
700 1 _ |a Masala, Giovanna
|b 10
700 1 _ |a Tagliabue, Giovanna
|b 11
700 1 _ |a Simeon, Vittorio
|b 12
700 1 _ |a Tumino, Rosario
|b 13
700 1 _ |a Milani, Lorenzo
|b 14
700 1 _ |a Derksen, Jeroen W G
|b 15
700 1 _ |a van der Schouw, Yvonne T
|b 16
700 1 _ |a Nøst, Therese Haugdahl
|b 17
700 1 _ |a Borch, Kristin Benjaminsen
|b 18
700 1 _ |a Sandanger, Torkjel M
|b 19
700 1 _ |a Quirós, J Ramón
|b 20
700 1 _ |a Rodriguez-Barranco, Miguel
|b 21
700 1 _ |a Bonet, Catalina
|b 22
700 1 _ |a Aizpurua-Atxega, Amaia
|b 23
700 1 _ |a Cirera, Lluís
|b 24
700 1 _ |a Guevara, Marcela
|b 25
700 1 _ |a Sundström, Björn
|b 26
700 1 _ |a Winkvist, Anna
|b 27
700 1 _ |a Heath, Alicia K
|b 28
700 1 _ |a Gunter, Marc J
|b 29
700 1 _ |a Weiderpass, Elisabete
|b 30
700 1 _ |a Johansson, Mattias
|b 31
700 1 _ |a Ferrari, Pietro
|b 32
773 _ _ |a 10.1038/s41598-024-66772-w
|g Vol. 14, no. 1, p. 16330
|0 PERI:(DE-600)2615211-3
|n 1
|p 16330
|t Scientific reports
|v 14
|y 2024
|x 2045-2322
856 4 _ |u https://inrepo02.dkfz.de/record/291781/files/s41598-024-66772-w.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/291781/files/s41598-024-66772-w.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:291781
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:11:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:11:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:11:06Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:11:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-24
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-24
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-24
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21